GA
ABMD

Geneva Advisors’s Abiomed Inc ABMD Stock Holding History

Geneva Advisors’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$1.62M Buy
+11,330
New +$1.52M 0.03% 270
2016
Q4 		– Sell
-2,213
Closed -$285K – 820
2016
Q3 		$285K Buy
+2,213
New +$265K 0.01% 589
2015
Q4 		– Sell
-5,365
Closed -$498K – 698
2015
Q3 		$498K Buy
+5,365
New +$473K 0.01% 390

Other funds holding ABMD

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geneva Advisors's ABMD Position: Q2 2017 in Review

Geneva Advisors opened a new position in Abiomed Inc (ABMD) in Q2 2017: 11,330 shares worth $1.62M. The stake represents 0.03% of the portfolio and ranks #270 among its holdings. This is a return to the name: Geneva Advisors previously reported a position in ABMD as recently as Q3 2016.

Geneva Advisors first reported a position in ABMD in Q3 2015 and has held it in 3 quarters since. 303 funds tracked by Wall St. Rank hold ABMD as of Q2 2017.

  • Geneva Advisors held 11,330 shares of Abiomed Inc worth $1.62M as of Q2 2017.
  • Abiomed Inc was a new Geneva Advisors position in Q2 2017.
  • Abiomed Inc made up 0.03% of Geneva Advisors's portfolio in Q2 2017, its #270 holding.
  • Geneva Advisors first reported a position in Abiomed Inc in Q3 2015 and has held it in 3 quarters since.
  • 303 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.